Leonard Sank - 05 Jun 2025 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)

Reporting relationship: Director
Issuer ticker: ORMP
Reported as of: 05 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2025, 16:07:47 UTC
Prior SEC filing: 08 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Leonard Sank

Key filing fact

Leonard Sank filed Form 4 for ORAMED PHARMACEUTICALS INC. (ORMP) on 09 Jun 2025.

Key facts

This page summarizes Leonard Sank's Form 4 filing for ORAMED PHARMACEUTICALS INC. (ORMP).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 09 Jun 2025, 16:07.

Change

Previous filing in this sequence was filed on 08 Jan 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001416089 Primary reporting owner

Sank Leonard

Relationship: Director
Address: 3 BLAIR ROAD, CAPE TOWN, SOUTH AFRICA
Signature: /s/ Leonard Sank
Signature date: 09 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORMP transaction

Common Stock

Award

Transaction value
Shares: +30,000
Change %: +31%
Price
Shares after: 128,021
Date: 05 Jun 2025
Ownership: Direct
Footnotes: F1

ORMP transaction

Common Stock

Award

Transaction value
Shares: +6,510
Change %: +5.1%
Price
Shares after: 134,531
Date: 05 Jun 2025
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents Restricted Stock Units ("RSUs") that will vest in equal portions of 10,000 as follows: January 1, 2026, January 1, 2027 and January 1, 2028. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

Footnote F2

Represents RSUs that will vest in equal installments as follows: on grant, July 1, 2025, October 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.